MarketPulse
M

$MAZE

2 articles found
1 positive
0 negative
1 neutral
The Motley FoolThe Motley Fool··Adé Hennis

Maze Therapeutics President Liquidates Full Position Ahead of Q4 Earnings

Maze Therapeutics president Harold Bernstein sold all 30,000 shares for $1.51M via pre-arranged trading plan, weeks before Q4 earnings report.
MAZEclinical-stage biotechearnings report
The Motley FoolThe Motley Fool··Adé Hennis

Maze Therapeutics CMO Completes Share Divestiture Amid Positive Clinical Momentum

Maze Therapeutics CMO sold 15,000 shares via pre-arranged plan, completing divestiture. He retains 300,000 options while company maintains positive clinical momentum.
MAZEIPOclinical trials